1	Title: Hypertension among persons living with HIV — Zambia, 2021; A cross-sectional study of a national		
2	electronic health record system		
3			
4	<i>Authors</i> : Jonas Z. Hines ¹ , Jose Tomas Prieto ² , Megumi Itoh ¹ , Sombo Fwoloshi ^{3,4} , Khozya D. Zyambo ³ ,		
5	Dalila Zachary¹, Cecilia Chitambala¹, Peter A. Minchella¹, Lloyd B. Mulenga³, Simon Agolory¹		
6			
7	Affiliations:		
8	1. U.S. Centers for Disease Control and Prevention, Lusaka, Zambia		
9	2. Palantir Technologies, Paris, France		
10	3. Ministry of Health, Lusaka, Zambia		
11	4. University of Zambia, School of Medicine		
12			
13	Keywords: Hypertension; Prevalence; HIV; Epidemiology; Non-communicable diseases; Zambia; Africa		
14			
15	Corresponding author:		
16	Jonas Hines		
17	U.S. Centers for Disease Control & Prevention (CDC) Zambia		
18	351 Independence Avenue, Woodlands, Lusaka, Zambia		
19	Phone: +260-211-257515		
20	Email: jhines1@cdc.gov		
21			
22			

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

1.2]).

2

Abstract (word count: 337) Background Hypertension is a major risk factor for cardiovascular disease, which is a common cause of death in Zambia. Data on hypertension prevalence in Zambia are scarce and limited to specific geographic areas and/or populations. We measured hypertension prevalence among persons living with HIV (PLHIV) in Zambia using a national electronic health record (EHR) system. Methods We did a cross-sectional study of hypertension prevalence among PLHIV aged ≥18 years in Zambia during 2021. Data were extracted from the SmartCare EHR, which covers ~90% of PLHIV on treatment in Zambia. PLHIV with ≥2 recorded blood pressure (BP) readings in 2021 were included. Hypertension was defined as ≥2 elevated BP readings (i.e., systolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg) during 2021 and/or on anti-hypertensive medication recorded in their EHR in the past five years. Multivariable logistic regression was used to assess associations between hypertension and independent variables. Results Among 750,098 PLHIV aged ≥18 years with ≥2 visits in SmartCare during 2021, 101,363 (13.5%) had ≥2 blood pressure readings recorded in their EHR. Among these PLHIV, 14.7% (95% confidence interval [CI]: 14.5-14.9) had hypertension during 2021. Only 8.9% of PLHIV with hypertension had an antihypertensive medication recorded in their EHR. The odds of hypertension were greater in older age groups compared to PLHIV aged 18-29 years (adjusted odds ratio [aOR] for 30-44 years: 2.6 [95% CI: 2.4-2.9]; aOR for 45-49 years: 6.4 [95% CI: 5.8-7.0]; aOR for ≥60 years: 14.5 [95% CI: 13.1-16.1]), urban areas (aOR: 1.9 [95% CI: 1.8-2.1]), and persons prescribed ART for ≥6-month at a time (aOR: 1.1 [95% CI: 1.0-

Discussion

Hypertension was common among a cohort of PLHIV in Zambia, with few having documentation of being on antihypertensive treatment. Most PLHIV were excluded from the analysis because of missing BP measurements in their EHR. Strengthening integrated management of non-communicable diseases in ART clinics might help to diagnose and treat hypertension in Zambia. Data completeness needs to be improved to routinely capture cardiovascular disease risk factors, including blood pressure readings consistently for PHLIV in their EHRs.

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

4

Article (word count: 2,636) **Backaround** Non-communicable diseases are common causes of death in sub-Saharan African countries (1). In Zambia, a country in southern Africa, cerebrovascular accidents (CVAs) and ischemic heart disease are among most common causes of death (2,3). With widespread availability of antiretroviral therapy (ART), non-communicable diseases are increasingly a major cause of morbidity among persons living with HIV (PLHIV) (4,5), including in Zambia (6,7). Hypertension is a known major risk factor for CVA and other cardiovascular diseases. Although country-specific data on prevalence of hypertension in sub-Saharan African countries is limited, one meta-analysis estimated prevalence to be 16% (8). PLHIV are at increased risk for noncommunicable diseases including cardiovascular disease (4,9-11). This risk might be attributed to effects of HIV (i.e., chronic inflammation) and/or side effects (e.g., metabolic syndrome, renal disease) of some ART (12,13). Some studies indicate PLHIV have a higher hypertension prevalence than people without HIV (14,15), with roughly 20-25% of PLHIV globally estimated to have hypertension (5,16,17). However, in sub-Saharan Africa, where most PLHIV reside, hypertension prevalence is not well-characterized at national levels and it is unclear if the prevalence of hypertension differs between PLHIV compared to people without HIV (15,18–20). Data on hypertension prevalence in Zambia are limited. In the 2018 Zambia Demographic and Health Survey, self-reported hypertension prevalence among women was 8.8% (this information was not ascertained from male participants) (21). Studies that objectively measure blood pressure have been limited geographically and/or conducted in special populations (7,22-26). For instance, in one study among PLHIV in Lusaka, hypertension prevalence was 6.4%, of which only one-half of persons were

aware of their hypertension diagnosis (23). Notably, approximately one-quarter of PLHIV with

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

5

hypertension in that study had suffered a major cardiovascular event, including CVA or myocardial infarction. Thus, current estimates of hypertension among PLHIV in Zambia give an incomplete picture. In this study, we sought to measure the proportion of PLHIV with hypertension using data routinely captured in a national electronic health record (EHR) system, SmartCare EHR. Methods We conducted a cross-sectional study of hypertension among PLHIV aged ≥18 years in Zambia from January to December 2021 (the last full calendar year of data available). We analyzed data from the SmartCare EHR, which was introduced for the HIV program in the early 2000s and has been scaled-up nationally since then. SmartCare EHR supports clinical care by providing patients with their longitudinal health record at any facility operating the EHR. As of 2021, SmartCare EHR was in use in ~1,500 Zambian health facilities that provide care for approximately 90% of PLHIV on ART in Zambia. Digitized SmartCare EHR data from health facilities are routinely consolidated and de-duplicated at the district and provincial levels, transported to Zambia MOH headquarters in Lusaka, and stored in Zambia's National Data Warehouse. All patient interactions (including clinical, pharmacy, and laboratory visits) at health facilities utilizing SmartCare EHR are recorded and data for most patients are entered into the system in real-time. In cases where health facilities record data on paper forms for retroactive data entry into SmartCare EHR, the process is completed prior to consolidation. Data from inpatient care are not captured in SmartCare EHR.

De-identified demographic data, clinical information, and pharmacy records were extracted from Zambia's SmartCare EHR system. Data were extracted for demographic characteristics, past medical history, medications, blood pressure measurements, height and weight, and laboratory data (CD4+ count, HIV viral load, and creatinine). Data are cleaned upon ingestion in Foundry (Palantir Technologies, Paris, France) by casting laboratory tests results values and physical measurements to numeric format. For some variables (i.e., non-HIV past medical history, diet, amount of physical activity, smoking history, blood cholesterol levels, and blood glucose) data were either completely missing or too sparse to analyze (i.e., <1% complete). Only PLHIV aged ≥18 years with ≥2 clinical visits in 2021 were eligible for inclusion in the study (in Zambia, BP is measured at each clinical visit but not necessarily at other patient interactions captured in SmartCare EHR [e.g., lab check, pharmacy pick-up]).

We defined elevated blood pressure as a systolic blood pressure reading of ≥140 mmHg or diastolic blood pressure readings of ≥90 mmHg. We defined hypertension as having ≥2 systolic blood pressure (SBP) readings of ≥90 mmHg or ≥2 diastolic blood pressure (DBP) readings of ≥90 mmHg (27) during

we defined elevated blood pressure as a systolic blood pressure reading of \geq 140 mmHg or diastolic blood pressure readings of \geq 90 mmHg. We defined hypertension as having \geq 2 systolic blood pressure (SBP) readings of \geq 140 mmHg or \geq 2 diastolic blood pressure (DBP) readings of \geq 90 mmHg (27) during 2021, or any PLHIV prescribed an antihypertensive medication in SmartCare EHR (including amiloride, amlodipine, atenolol, carvedilol, enalapril, furosemide, hydralazine, hydrochlorothiazide, losartan, methyldopa, metoprolol, nifedipine, spironolactone, telmisartan, and valsartan) in the past five years. Because past medical history was not well captured in the EHR, we could not include persons with a historical hypertension diagnosis regardless of BP measurement readings during 2021. Among PLHIV with hypertension, we defined grade 2 hypertension as \geq 1 reading with systolic blood pressure \geq 160 mmHg or diastolic blood pressure \geq 100 mmHg and hypertensive urgency as \geq 1 reading with systolic blood pressure \geq 180 mmHg or diastolic blood pressure \geq 110 mmHg (27).

Results

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

8

hypertensive medication recorded in their EHR. Among any PLHIV with an anti-hypertensive medication

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

9

patients). Other studies in Zambia indicate suboptimal levels of hypertension treatment and control

(21,23), which is similar to other countries in Africa (20,31,32). Integrating noncommunicable disease

care into routine HIV care might increase prevention, diagnosis, and management of hypertension in Zambia, potentially reducing cardiovascular disease-related morbidity and mortality (33). Although most PLHIV were excluded from the study because of missing BP data, to our knowledge, this analysis is the largest cohort study of hypertension among PLHIV.

That many hypertensive PLHIV still had elevated blood pressure readings despite antihypertensive treatment is demonstrative of the challenge of controlling hypertension even when treated (20,31,32); nevertheless this finding warrants action, with a focus on strategies to increase treatment of PLHIV with existing hypertension in Zambia and measures to prevent hypertension among those without it. Being older and overweight are established risk factors for hypertension, including among PLHIV (11,20). The

dwelling PLHIV consuming higher sodium diets or greater pollution exposure than those in rural areas) and/or be an artifact of poor data quality (i.e., highest proportion of PLHIV with hypertension observed in provinces that also had better data completeness).

Some reports link ART use with increased prevalence of hypertension among PLHIV in Africa (7,34,35). Although we could not assess this relationship in this study that was confined to PLHIV on ART, longer ART duration was not associated with hypertension, which is in contrast to findings from several other

observed geographic patterns of hypertension could be related to regional differences in diet (i.e., urban

studies from countries in Africa (17,36). Some types of ART have been associated with hypertension (37), but in this analysis there were no associations between ART regimens and hypertension in the multivariable model.

The association of elevated BMI for PLHIV on dolutegravir-based regimens in this analysis could signify metabolic syndrome among these persons, with a potential side effect of integrase inhibitors (38); we

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

were not able to analyze glucose or lipid measurements to confirm this hypothesis. However, because many PLHIV in Zambia were transitioned to dolutegravir-based regimens from different ART regimens (i.e., efavirenz-based regimens) in the recent past, the elevated BMI among participants could also predate their transition to dolutegravir-based regimens so a different study design (i.e., cohort study) is warranted to further explore this potential signal. Nevertheless, the superior HIV viral load control and lower risk of HIV treatment failure make dolutegravir the preferred regimen in Zambia and other countries with generalized HIV epidemics (39).

The study had several limitations. Most importantly, blood pressure data completeness was very low, with only approximately one-eighth of PLHIV in the dataset being analyzed. Despite this limitation, this is one of the largest studies of hypertension reported from sub-Saharan Africa to date and provides the first national level study of hypertension in Zambia. However, the estimate is not nationally representative and, furthermore, only represents an estimate among PLHIV in care who were captured by the SmartCare EHR. Comparison to non-HIV-infected persons was not possible, but as SmartCare EHR is integrated into other care settings in Zambia, this will become possible. For some variables, high amounts of missingness precluded their inclusion in the multivariable model and, furthermore, some important variables (e.g., non-HIV past medical history) were not available. Additionally, past medical history was not captured in the dataset, so the proportion of PLHIV with diagnosed hypertension could not be assessed. Furthermore, very few records had a blood pressure medication documented. This could reflect low levels of hypertension treatment, limited availability of sphygmomanometers, or could result from data entry omissions at the point-of-care. If antihypertensive medications were not consistently recorded, then the true prevalence of hypertension among PLHIV in Zambia is likely higher. Next, only blood pressure readings occurring over a one-year period were assessed. This approach reduced the likelihood that two elevated blood pressure measurements were separated by long periods

of time, but also led to the exclusion of blood pressure measurements that occurred outside of the defined period potentially affecting the hypertension estimates. Lastly, the EHR does not capture inpatient data, so information on consequences of uncontrolled hypertension (e.g., stroke or myocardial infarction) were not available.

This analysis points to a need to improve hypertension management for PLHIV in Zambia. Some of the existing practices that rely on referring patients with elevated BPs to the outpatient department (i.e., urgent care) for further evaluation might result in patient attrition, missing opportunities to adequately manage this common comorbidity among PLHIV in Zambia. Integrated primary care models for PLHIV have better outcomes for non-communicable disease management (40), and can even result in better viral suppression (41). ART clinics in Zambia might benefit from instituting integrated management of noncommunicable diseases, including life-style modification, anti-hypertensive therapy with appropriate treatment intensification, and medication adherence assessments for hypertension (42). An integrated primary care model for conditions like hypertension is possible in countries like Zambia and can improve patient outcomes (32,33). With integration, multi-month dispensing is a promising approach for comanagement of HIV and hypertension (43).

Routinely monitoring for hypertension, along with documenting other health measures (e.g., diet, smoking status, BMI) in the EHR would not only allow medical providers to determine client's cardiovascular risk for CVAs or other cardiovascular events and target treatment, but also might provide data needed to identify specific health facilities or clinicians that would benefit from educational interventions in management of these risk factors and conditions. EHRs like SmartCare are promising data sources for noncommunicable diseases surveillance given their reach, routine use in clinical setting, and richness of information. For this to be successful, data completeness needs to be improved to

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

the official position of the funding agencies

PEPFAR Funding Acknowledgment

This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) through a cooperative agreement with the Zambia Ministry of Health and a cooperative agreement with Palantir Technologies

Conflict of interest statement

The authors have no conflicts to disclose

References

302

303

304

305

307

309

- 1. Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258).
- Institute for Health Metrics and Evaluation. Zambia: What causes the most deaths? [Internet].
- 308 3. Mapoma CC, Munkombwe B, Mwango C, Bwalya BB, Kalindi A, Gona NP. Application of verbal

autopsy in routine civil registration in Lusaka District of Zambia. BMC Health Serv Res.

[cited 2020 Nov 17]. Available from: http://www.healthdata.org/zambia

- 310 2021;21(1):1–11.
- Shah AS V, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global Burden of Atherosclerotic
 Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis.
- 313 Circulation. 2018 Sep;138(11):1100–12.
- 5. Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabuddhe V V, Peprah E, et al.
- Noncommunicable diseases among HIV-infected persons in low-income and middle-income
- 316 countries: a systematic review and meta-analysis. AIDS. 2018 Jul;32 Suppl 1(Suppl 1):S5–20.
- 6. Cheelo M. Top causes of Mortality among Community Deaths in Zambia, 2020-2021. In: Annual
- 318 National HIV/TB/COVID-19/Hepataitis B Technical Conference. Lusaka, Zambia; 2021.
- 319 7. Musekwa R, Hamooya BM, Koethe JR, Nzala S, Masenga SK. Prevalence and correlates of
- 320 hypertension in HIV-positive adults from the Livingstone Central Hospital, Zambia. Pan Afr Med J.
- 321 2021;39:237.
- 322 8. Twagirumukiza M, De Bacquer D, Kips JG, de Backer G, Stichele R Vander, Van Bortel LM. Current
- and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat:
- an estimate from population studies. J Hypertens. 2011 Jul;29(7):1243–52.
- 325 9. Benjamin LA, Corbett EL, Connor MD, Mzinganjira H, Kampondeni S, Choko A, et al. HIV,

326		antiretroviral treatment, hypertension, and stroke in Malawian adults: A case-control study.
327		Neurology. 2016 Jan;86(4):324–33.
328	10.	Walker RW, Jusabani A, Aris E, Gray WK, Unwin N, Swai M, et al. Stroke risk factors in an incident
329		population in urban and rural Tanzania: a prospective, community-based, case-control study.
330		Lancet Glob Heal. 2013 Nov;1(5):e282-8.
331	11.	Ake JA, Polyak CS, Crowell TA, Kiweewa F, Semwogerere M, Maganga L, et al. Noninfectious
332		Comorbidity in the African Cohort Study. Clin Infect Dis. 2019;69(4).
333	12.	Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults.
334		J Infect Dis. 2012 Jun;205 Suppl(Suppl 3):S375-82.
335	13.	Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination
336		antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003
337		Nov;349(21):1993–2003.
338	14.	Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US Patients with Prevalent HIV
339		Infection - A Trend Analysis. In: Journal of Infectious Diseases. 2017.
340	15.	Davis K, Perez-Guzman P, Hoyer A, Brinks R, Gregg E, Althoff KN, et al. Association between HIV
341		infection and hypertension: a global systematic review and meta-analysis of cross-sectional
342		studies. BMC Med. 2021;19(1).
343	16.	Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a
344		systematic review and meta-analysis. J Am Soc Hypertens. 2017 Aug;11(8):530–40.
345	17.	Bigna JJ, Ndoadoumgue AL, Nansseu JR, Tochie JN, Nyaga UF, Nkeck JR, et al. Global burden of
346		hypertension among people living with HIV in the era of increased life expectancy: a systematic
347		review and meta-analysis. J Hypertens. 2020 Sep;38(9):1659–68.
348	18.	Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART
349		with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J

- 350 Epidemiol. 2013 Dec;42(6):1754-71. 351 19. Mogaka JN, Sharma M, Temu T, Masyuko S, Kinuthia J, Osoti A, et al. Prevalence and factors 352 associated with hypertension among adults with and without HIV in Western Kenya. PLoS One. 353 2022;17(1):e0262400. Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, et al. Population-Based 354 20. 355 Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016;11(5):e0156309. 356 357 21. Zambia Statistics Agency, Ministry of Health, University Teaching Hospital Virology laboratory, 358 ICF. Zambia Demographic and Health Survey 2018. 2019;540. 359 22. Yan LD, Chi BH, Sindano N, Bosomprah S, Stringer JS, Chilengi R. Prevalence of hypertension and 360 its treatment among adults presenting to primary health clinics in rural Zambia: analysis of an 361 observational database. BMC Public Health. 2015 Sep;15:933. 362 23. Bauer S, Wa Mwanza M, Chilengi R, Holmes CB, Zyambo Z, Furrer H, et al. Awareness and 363 management of elevated blood pressure among human immunodeficiency virus-infected adults 364 receiving antiretroviral therapy in urban Zambia: a call to action. Glob Health Action. 365 2017;10(1):1359923. Rush KL, Goma FM, Barker JA, Ollivier RA, Ferrier MS, Singini D. Hypertension prevalence and risk 366 24. 367 factors in rural and urban Zambian adults in western province: a cross-sectional study. Pan Afr 368 Med J. 2018;30:97. 369 Mulenga D, Siziya S, Rudatsikira E, Mukonka VM, Babaniyi O, Songolo P, et al. District specific 25. 370 correlates for hypertension in Kaoma and Kasama rural districts of Zambia. Rural Remote Health. 371 2013;13(3):2345.
- Goma FM, Nzala SH, Babaniyi O, Songolo P, Zyaambo C, Rudatsikira E, et al. Prevalence of
 hypertension and its correlates in Lusaka urban district of Zambia: a population based survey. Int

374 Arch Med [Internet]. 2011;4(1):34. Available from: http://www.intarchmed.com/content/4/1/34 375 27. Unger T. Borghi C. Charchar F. Khan NA. Poulter NR. Prabhakaran D. et al. 2020 International 376 Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6). 377 Stevenson M, Sergeant E, Nunes T, Heuer C, Marshall J, Sanchez J, et al. epiR: Tools for the 28. 378 Analysis of Epidemiological Data [Internet]. 2021. Available from: https://cran.r-379 project.org/package=epiR 29. Nutakki A, Chomba M, Chishimba L, Zimba S, Gottesman RF, Bahouth MN, et al. Risk factors and 380 381 outcomes of hospitalized stroke patients in Lusaka, Zambia. J Neurol Sci. 2021 May;424:117404. 382 30. Kapombe P, Cheelo M, Kamalonga K, Tally L, Stoops E, Mwango C, et al. Most common causes of 383 death in Zambia by HIV status, 2020-2021. In: AIDS 2022. Montreal, Canada; 2022. 384 31. Muddu M, Tusubira AK, Sharma SK, Akiteng AR, Ssinabulya I, Schwartz JI. Integrated 385 Hypertension and HIV Care Cascades in an HIV Treatment Program in Eastern Uganda: A 386 Retrospective Cohort Study. J Acquir Immune Defic Syndr. 2019 Aug;81(5):552-61. 387 32. Heller DJ, Balzer LB, Kazi D, Charlebois ED, Kwarisiima D, Mwangwa F, et al. Hypertension testing 388 and treatment in Uganda and Kenya through the SEARCH study: An implementation fidelity and outcome evaluation. PLoS One. 2020;15(1):e0222801. 389 390 Hickey MD, Ayieko J, Owaraganise A, Sim N, Balzer LB, Kabami J, et al. Effect of a patient-33. 391 centered hypertension delivery strategy on all-cause mortality: Secondary analysis of SEARCH, a 392 community-randomized trial in rural Kenya and Uganda. PLoS Med. 2021 Sep;18(9):e1003803. Nduka CU, Stranges S, Sarki AM, Kimani PK, Uthman OA. Evidence of increased blood pressure 393 34. 394 and hypertension risk among people living with HIV on antiretroviral therapy: a systematic 395 review with meta-analysis. J Hum Hypertens. 2016 Jun;30(6):355–62. 396 35. Lubega G, Mayanja B, Lutaakome J, Abaasa A, Thomson R, Lindan C. Prevalence and factors 397 associated with hypertension among people living with HIV/AIDS on antiretroviral therapy in


398 Uganda. Pan Afr Med J. 2021;38:216. 399 36. Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly 400 active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 401 2003. AIDS. 2005 Jun;19(9):953-60. 402 37. van Zoest RA, Wit FW, Kooij KW, van der Valk M, Schouten J, Kootstra NA, et al. Higher 403 prevalence of hypertension in HIV-1-infected patients on combination antiretroviral therapy is 404 associated with changes in body composition and prior stavudine exposure. Clin Infect Dis. 405 2021;63(2). 406 38. Hamooya BM, Mulenga LB, Masenga SK, Fwemba I, Chirwa L, Siwingwa M, et al. Metabolic 407 syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: 408 Prevalence and associated factors. Medicine (Baltimore). 2021 Apr;100(14):e25236. 409 39. Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, et al. Risks and benefits of 410 dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet 411 HIV [Internet]. 2019 Feb 1;6(2):e116-27. Available from: https://doi.org/10.1016/S2352-412 3018(18)30317-5 40. Appenheimer A Ben, Bokhour B, McInnes DK, Richardson KK, Thurman AL, Beck BF, et al. Should 413 Human Immunodeficiency Virus Specialty Clinics Treat Patients With Hypertension or Refer to 414 415 Primary Care? An Analysis of Treatment Outcomes. Open forum Infect Dis. 2017;4(1):ofx005. 416 41. Hoang T, Goetz MB, Yano EM, Rossman B, Anaya HD, Knapp H, et al. The impact of integrated HIV care on patient health outcomes. Med Care. 2009 May;47(5):560-7. 417

- 42. Topp SM, Chipukuma JM, Chiko MM, Matongo E, Bolton-Moore C, Reid SE. Integrating HIV

 treatment with primary care outpatient services: Opportunities and challenges from a scaled-up

 model in Zambia. Health Policy Plan. 2013;28(4).
- 421 43. Kimera ID, Namugenyi C, Schwartz JI, Musimbaggo DJ, Ssenyonjo R, Atukunda P, et al. Integrated

multi-month dispensing of antihypertensive and antiretroviral therapy to sustain hypertension and HIV control. J Hum Hypertens. 2022 Mar;1–7.



Figures and Tables

Figure 1. Sample size flow diagram for analysis of persons living with HIV with hypertension in Zambia, 2021

^{*} This is the population which was eligible for inclusion in the analysis

Table 1. Comparison of the variable distribution and completeness in the entire and analytic datasets for hypertension among persons living with HIV — Zambia, 2021

Variable	Entire dataset, n (%)	Analytic dataset, n (%)	p-value
	(N=1,236,040)	(N=101,363)	
Sex	7 04 000 (60 0)	c= ==0 (c + =)	.0.04
Female	781,829 (63.3)	65,570 (64.7)	<0.02
Male	454,211 (36.7)	35,793 (35.3)	
Age group			
18-29 years	232,099 (18.8)	16,191 (16.0)	< 0.01
30-44 years	585,455 (47.4)	45,850 (45.2)	
45-59 years	350,092 (28.3)	32,681 (32.2)	
≥60 years	68,394 (5.5)	6,641 (6.6)	
Province			
Central	125,704 (10.2)	2,813 (2.8)	<0.01
Copperbelt	238,609 (19.3)	7,197 (7.1)	
Eastern	105,595 (8.5)	3,672 (3.6)	
Luapula	55,168 (4.5)	54.0 (0.1)	
Lusaka	343,981 (27.8)	45,414 (44.8)	
Muchinga	32,978 (2.7)	512 (0.5)	
Northern	52,014 (4.2)	58.0 (0.1)	
Northwestern	36,016 (2.9)	1,893 (1.9)	
Southern	128,299 (10.4)	35,082 (34.6)	
Western	91,156 (7.4)	4,120 (4.1)	
Missing	26,520 (2.1)	548 (0.5)	
Urban/rural designation			
Rural	387,472 (31.3)	18,454 (18.2)	< 0.01
Urban	736,921 (59.6)	78,123 (77.1)	
Missing	111,647 (9.0)	4,786 (4.7)	
Years on ART			
0-1	340,014 (27.5)	19,087 (18.8)	< 0.01
2-4	419,400 (33.9)	28,182 (27.8)	
5-9	301,575 (24.4)	32,408 (32.0)	
≥10	175,051 (14.2)	21,686 (21.4)	
Current ART regimen	, , ,	, , ,	
Efavirenz-based	49,083 (4.0)	1,423 (1.4)	< 0.01
Dolutegravir-based	1,137,837 (92.1)	97,049 (95.7)	
Both efavirenz and dolutegravir listed	3,291 (0.3)	133 (0.1)	
Other	45,829 (3.7)	2,758 (2.7)	
Most recent ART prescription length	.5,525 (5.7)	2,700 (2.7)	
<3 months	141,776 (11.5)	6,275 (6.2)	<0.03
3-5 months	373,549 (30.2)	27,839 (27.5)	.0.01
6+ months	720,706 (58.3)	67,249 (66.3)	
טי וווטוונווט	720,700 (36.3)	07,245 (00.5)	

336,236 (27.2) 59,860 (4.8)	51,056 (50.4)	<0.01
		< 0.01
59,860 (4.8)		10.01
	8,776 (8.7)	
107,253 (8.7)	19,668 (19.4)	
53,674 (4.3)	10,585 (10.4)	
679,017 (54.9)	11,278 (11.1)	
62,431 (5.1)	7,694 (7.6)	< 0.01
61,544 (5.0)	7,195 (7.1)	
107,473 (8.7)	12,847 (12.7)	
100,4592 (81.3)	73,627 (72.6)	
59,590 (4.8)	6,994 (6.9)	< 0.01
101,297 (8.2)	12,567 (12.4)	
369,859 (29.9)	49,690 (49.0)	
705,294 (57.1)	32,112 (31.7)	
975,952 (79.0)	92,115 (90.9)	< 0.01
16,881 (1.4)	1,494 (1.5)	
26,338 (2.1)	2,595 (2.6)	
216,869 (17.5)	5,159 (5.1)	
36,457 (2.9)	8,892 (8.8)	< 0.01
5,829 (0.5)	1,254 (1.2)	
119,3754 (96.6)	91,217 (90.0)	
495,498 (40.1)	73,406 (72.4)	< 0.01
552,109 (44.7)	17,197 (17.0)	
188,433 (15.2)	10,760 (10.6)	
	107,253 (8.7) 53,674 (4.3) 679,017 (54.9) 62,431 (5.1) 61,544 (5.0) 107,473 (8.7) 100,4592 (81.3) 59,590 (4.8) 101,297 (8.2) 369,859 (29.9) 705,294 (57.1) 975,952 (79.0) 16,881 (1.4) 26,338 (2.1) 216,869 (17.5) 36,457 (2.9) 5,829 (0.5) 119,3754 (96.6) 495,498 (40.1) 552,109 (44.7)	107,253 (8.7) 19,668 (19.4) 53,674 (4.3) 10,585 (10.4) 679,017 (54.9) 11,278 (11.1) 62,431 (5.1) 7,694 (7.6) 61,544 (5.0) 7,195 (7.1) 107,473 (8.7) 12,847 (12.7) 100,4592 (81.3) 73,627 (72.6) 59,590 (4.8) 6,994 (6.9) 101,297 (8.2) 12,567 (12.4) 369,859 (29.9) 49,690 (49.0) 705,294 (57.1) 32,112 (31.7) 975,952 (79.0) 92,115 (90.9) 16,881 (1.4) 1,494 (1.5) 26,338 (2.1) 2,595 (2.6) 216,869 (17.5) 5,159 (5.1) 36,457 (2.9) 8,892 (8.8) 5,829 (0.5) 1,254 (1.2) 119,3754 (96.6) 91,217 (90.0) 495,498 (40.1) 73,406 (72.4) 552,109 (44.7) 17,197 (17.0)

Variables are based on data from the most recent patient interaction in the electronic health record

^{* 38.9%} of recent CD4+ count measurements were from 2020 or 2021

[†] 98.4% of recent viral load measurements were from 2020 or 2021

 $^{^{\}ddagger}$ Elevated creatinine defined as ≥115 µmol/L in men and ≥98 µmol/L in women ART: antiretroviral therapy

Table 2. Hypertension prevalence and odds ratios of hypertension among persons living with HIV — Zambia, 2021 (N=101,363)*

	Prevalence, %	OR (95% CI)	aOR (95% CI) [†]
Overall	14.7		
Sex			
Female	13.7	Referent	Referen
Male	16.4	1.23 (1.19-1.28)	1 (0.96-1.04
Age group			
18-29 years	4.3	Referent	Referen
30-44 years	10.1	2.53 (2.33-2.75)	2.61 (2.39-2.85
45-59 years	21.6	6.19 (5.71-6.71)	6.36 (5.81-6.96
≥60 years	37.4	13.42 (12.26-14.7)	14.54 (13.14-16.09
Province			
Central	11.8	Referent	Referent
Copperbelt	18.1	1.65 (1.45-1.88)	1.25 (1.08-1.44)
Eastern	10.3	0.87 (0.74-1.01)	0.62 (0.5-0.78
Luapula	5.6	0.44 (0.14-1.42)	0.4 (0.09-1.67)
Lusaka	15.4	1.37 (1.22-1.54)	1.11 (0.97-1.26
Muchinga	3.7	0.29 (0.18-0.46)	0.37 (0.21-0.63)
Northern	10.3	0.87 (0.37-2.03)	1.23 (0.42-3.58
Northwestern	12.4	1.06 (0.88-1.26)	0.92 (0.76-1.11
Southern	14.6	1.28 (1.14-1.44)	0.97 (0.85-1.1
Western	8.9	0.73 (0.62-0.85)	0.78 (0.66-0.92)
Urban/rural designation			
Rural	9.0	Referent	Referen
Urban	16.0	1.92 (1.82-2.03)	1.93 (1.81-2.05
Years on ART			
0-1	10.8	Referent	Referen
2-4	12.8	1.21 (1.14-1.28)	1.04 (0.97-1.11
5-9	15.0	1.46 (1.38-1.54)	1.02 (0.95-1.08
≥10	20.1	2.09 (1.97-2.21)	1.07 (1.00-1.14
ART regimen [‡]			
Efavirenz-based	11.5	Referent	Referent
Dolutegravir-based	14.8	1.33 (1.13-1.57)	1.15 (0.96-1.38
Other	13.7	1.22 (1.00-1.48)	1.00 (0.80-1.24
Most recent ART prescription length			
<3 months	11.3	Referent	Referen
3-5 months	12.6	1.14 (1.04-1.24)	0.98 (0.89-1.09
≥6 months	15.9	1.48 (1.36-1.60)	1.11 (1.01-1.22
Body mass index (kg/m²)		•	
Normal (18.5-24.9)	11.6	Referent	
Low (<18.5)	8.6	0.72 (0.66-0.78)	
Overweight (25-29.9)	19.9	1.9 (1.82-1.99)	

Obesity (≥30.0)	28.7	3.08 (2.93-3.24)	
Initial CD4+ count (cells/mm³)			
0-200	15.2	Referent	
201-350	15.0	0.98 (0.9-1.07)	
>350	13.6	0.87 (0.81-0.95)	
Most recent CD4+ count (cells/mm³)			
0-200	15.2	Referent	
201-350	17.0	1.15 (1.06-1.24)	
>350	16.2	1.09 (1.01-1.16)	
Most recent viral load count (copies/mL)			
<1000	15.1	Referent	Referent
1,000-9,999	11.5	0.73 (0.62-0.86)	0.96 (0.81-1.14)
≥10,000	10.9	0.69 (0.61-0.78)	1.02 (0.89-1.17)
Most recent creatinine ¶			
Normal creatinine	17.3	Referent	
Elevated creatinine	28.1	1.88 (1.64-2.15)	

^{*} Hypertension defined as ≥2 systolic blood pressure readings of ≥140 mmHg or ≥2 diastolic blood pressure readings of ≥90 mmHg among persons with ≥2 clinical visits during 2021

aOR: adjusted odds ratio; ART: antiretroviral therapy; CI: confidence interval; OR: odds ratio

[†] Adjusted for sex, age group, province, urban/rural designation, ART regimen, years on ART, script length, and body mass index

[‡] The most recently listed ART regimen in SmartCare electronic health record. If a regimen listed both dolutegravir and efavirenz, then it was excluded from the analysis (n= 128)

[¶] Elevated creatinine defined as \geq 115 µmol/L in men and \geq 98 µmol/L in women, corresponding to glomerular filtration rate of <60 mL/min/1.73m²

	Prevalence, %	OR (95% CI)	aOR (95% CI) [†]
Overall	12.4		
Blood pressure			
Not hypertensive [‡]	10.9	Referent	Referent
Hypertensive [‡]	18.7	1.88 (1.64-2.15)	1.36 (1.18-1.57)
Sex			
Female	11.1	Referent	Referent
Male	14.4	1.35 (1.2-1.52)	1.19 (1.06-1.35)
Age Group			
18-29 years	4.8	Referent	Referent
30-44 years	10.2	2.28 (1.8-2.89)	2.21 (1.75-2.81)
45-59 years	15.7	3.72 (2.95-4.69)	3.38 (2.67-4.28)
≥60 years	27.0	7.42 (5.69-9.68)	6.37 (4.85-8.37)

^{*} Elevated creatinine defined as \geq 115 µmol/L in men and \geq 98 µmol/L in women, corresponding to glomerular filtration rate of <60 mL/min/1.73m²

443

[†] Adjusted for presence/absence of hypertension, sex, and age group

[‡] Hypertension defined as as having ≥2 systolic blood pressure readings of ≥140 mmHg or ≥2 diastolic blood pressure readings of ≥90 mmHg during the study period aOR: adjusted odds ratio; CI: confidence interval; OR: odds ratio